Corrigendum to "N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression"[Eur. J. Med. Chem. 2020 Jan 1;185:111725]
Eur J Med Chem. 2020 Aug 1:199:112406.
doi: 10.1016/j.ejmech.2020.112406.
Epub 2020 May 11.
1 School of Pharmacy, College of Pharmacy, Taipei Medical University, Taiwan.
2 PhD Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taiwan.
3 Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
4 Ph.D. Program for the Clinical Drug Discovery from Botanical Herbs, College of Pharmacy, University, Taipei, Taiwan.
5 Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; Ph.D. Program for the Clinical Drug Discovery from Botanical Herbs, College of Pharmacy, University, Taipei, Taiwan.
6 Graduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
7 Ph.D. Program for the Clinical Drug Discovery from Botanical Herbs, College of Pharmacy, University, Taipei, Taiwan. Electronic address: mcchen1250@tmu.edu.tw.
8 School of Pharmacy, College of Pharmacy, Taipei Medical University, Taiwan; School of Pharmacy, National Defense Medical Center, Taipei, Taiwan; TMU Biomedical Commercialization Center, Taipei Medical University, Taiwan. Electronic address: jpl@tmu.edu.tw.